Literature DB >> 10537161

Expression of activin A and follistatin core proteins by human prostate tumor cell lines.

S J McPherson1, S L Mellor, H Wang, L W Evans, N P Groome, G P Risbridger.   

Abstract

Activin and follistatin (FS) messenger RNA and protein are expressed and localized to human prostate tissue from men with high grade cancer and to human prostate tumor cell lines LNCaP, DU145, and PC3. Although activin A induces apoptosis and inhibits cell proliferation in LNCaP cells, PC3 cells are insensitive to the effect of exogenous addition of activin A. The results of this study show that activin A and FS are produced and can be measured by specific enzyme-linked immunosorbent assays in PC3 cells and media but are not detectable in LNCaP cells. Over 10 days in culture, the production of activin A by PC3 cells declines and is inversely correlated (r = -0.779) to FS288 production, which steadily increases and is significantly elevated compared with Day 1 of culture. The presence of FS288 and FS315 proteins was confirmed by immunocytochemistry and showed that only PC3 cells produced the FS288 isoform. Western blotting of PC3 cell media confirmed the presence of the FS288 isoform. Blockade of FS288 activity with a neutralizing antibody rendered PC3 cells responsive to activin A, as measured by inhibition of proliferation. Collectively, these results suggest that PC3 tumor cells are insensitive to activin A because they produce measurable amounts of activin ligand and FS288 protein, which is capable of blocking the autocrine response of these cells to activin A.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10537161     DOI: 10.1210/endo.140.11.7141

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  12 in total

1.  Serum follistatin in patients with prostate cancer metastatic to the bone.

Authors:  Francesca Maria Tumminello; Giuseppe Badalamenti; Fabio Fulfaro; Lorena Incorvaia; Marilena Crescimanno; Carla Flandina; Maria Vittoria Sepporta; Gaetano Leto
Journal:  Clin Exp Metastasis       Date:  2010-07-11       Impact factor: 5.150

Review 2.  Clinical and Therapeutic Implications of Follistatin in Solid Tumours.

Authors:  Lei Shi; Jeyna Resaul; Sioned Owen; Lin Ye; Wen G Jiang
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

3.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Authors:  Andrea Pellagatti; Martin Jädersten; Ann-Mari Forsblom; Helen Cattan; Birger Christensson; Emma K Emanuelsson; Mats Merup; Lars Nilsson; Jan Samuelsson; Birgitta Sander; James S Wainscoat; Jacqueline Boultwood; Eva Hellström-Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

4.  Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines.

Authors:  Chris Planque; Vathany Kulasingam; Chris R Smith; Karen Reckamp; Lee Goodglick; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2009-09-23       Impact factor: 5.911

Review 5.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

6.  Peroxisome proliferator-activated receptor gamma down-regulates follistatin in intestinal epithelial cells through SP1.

Authors:  Brian M Necela; Weidong Su; E Aubrey Thompson
Journal:  J Biol Chem       Date:  2008-09-03       Impact factor: 5.157

7.  Activin C antagonizes activin A in vitro and overexpression leads to pathologies in vivo.

Authors:  Elspeth Gold; Niti Jetly; Moira K O'Bryan; Sarah Meachem; Deepa Srinivasan; Supreeti Behuria; L Gabriel Sanchez-Partida; Teresa Woodruff; Shelley Hedwards; Hong Wang; Helen McDougall; Victoria Casey; Birunthi Niranjan; Shane Patella; Gail Risbridger
Journal:  Am J Pathol       Date:  2008-12-18       Impact factor: 4.307

8.  Interaction of testosterone with inhibin alpha and betaA subunits to regulate prostate gland growth.

Authors:  Falah Shidaifat; Ibrahim Al-Zuhair; Zuhair Bani-Ismail
Journal:  Endocrine       Date:  2007-02       Impact factor: 3.633

9.  Activin receptor signaling regulates prostatic epithelial cell adhesion and viability.

Authors:  Derek P Simon; Sivan Vadakkadath Meethal; Andrea C Wilson; Miguel J Gallego; Stephanie L Weinecke; Erin Bruce; Patrick F Lyons; Ryan J Haasl; Richard L Bowen; Craig S Atwood
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

10.  Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer.

Authors:  P Balanathan; E D Williams; H Wang; J S Pedersen; L G Horvath; M G Achen; S A Stacker; G P Risbridger
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.